In a review of 25 patie-nts with pulmonary infection caused by unclassified mycobacteria the course of the disease is related to the method of treatment. Five patients were followed while not being treated; in four the disease progressed and in one it remained static, and in each case the organism persisted in the sputum. Sixteen patients were given combinations of streptomycin, isoniazid, and para-aminosalicylic acid for periods which varied between three months and two and a half years; there was bacteriological sputum conversion in six, although in each case the organism showed in vitro resistance to these drugs. Eleven patients were treated primarily with combinations of other anti-tuberculosis drugs for at least 12 consecutive weeks, after which the mycobacteria could no longer be cultured from the sputum in eight, in each case the organism showing in vitro sensitivity to the drugs. Ten patients received combined medical and surgical treatment, which was successful in eight and a failure in two, one of whom died post-operatively. A favourable response occurred most frequently when the disease was confined to one pulmonary radiographic zone and when less than 10 positive sputum cultures had been obtained. These results show that in this type of disease the response to chemotherapy is uncertain, in vitro drug sensitivity tests are of limited value, and combined medical and surgical treatment is usually effective.
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There are patients with pulmonary disease closely resembling tuberculosis from whom acid-fast bacilli are isolated which differ from Mycobacterium tuberculosis or Mycobacterium bovis. These micro-organisms, which constitute a heterogeneous group, have been variously described as anonymous, atypical, or unclassified mycobacteria, although none of these names is wholly appropriate. The unclassified mycobacteria, as they will be called here, are distinguishable from tubercle bacilli and from each other in several ways, notably by colonial morphology, pigment production, and rate of growth. The most widely used system of classification is that proposed by Runyon (1959) , who defined four main groups. Briefly, in group I (photochromogens) a yellow pigment is produced when colonies which have been cultured in darkness are exposed to light; in group II (scotochromogens) pigment is produced during culture in darkness; in group III (nonphotochromogens) there is little or no pigment production whatever the conditions of culture; and in group IV there is rapid growth and no 'Present address: Royal Free Hospital, Gray's Inn Road, London, W.C.1 pigment production. Other characteristic features of these organisms are their production of catalase but not of niacin, absence of pathogenicity for guinea-pigs, and frequent in vitro resistance to para-aminosalicylic acid (P.A.S.), isoniazid, and streptomycin (Runyon, 1959; Marks and Trollope, 1960) .
These bacteria are widely distributed in nature and their isolation from a patient is not necessarily of clinical significance. Thus casual strains may be inhaled and then expectorated or the sputum may become contaminated at the time of collection or at culture. However, in patients with chronic inflammatory disease of the lungs, from whom unclassified mycobacteria are isolated repeatedly, in the absence of other pathogens their aetiological significance must be presumed. In these cases the clinical, radiological, and pathological features may be indistinguishable from those of tuberculosis.
The role of these micro-organisms as human pathogens has been recognized only recently; experience of treatment is therefore limited and the most effective methods have yet to be determined. In this paper the course of the disease in Runyon (1959) .
In the majority of patients in this series, namely in 16 out of 25, organisms from group I were isolated. In Britain this is the group most often pathogenic for man (Public Health Laboratory Service, 1962) . Organisms from group III were cultured in six cases, from group II in two cases, and from group IV in one case (Table I) . PROGRESS AND TREATMENT The course of the disease in these 25 patients has been followed for periods of up to nine years, the length of followup varying according to the date of the first attendance at hospital. From the time of the first positive sputum culture the follow-up was for at least two years (or until death, if this occurred in less than two years) in 20 patients, for at least three years in 13, and for at least five years in eight.
For assessment of the effects of treatment two criteria of progress have been adopted, namely disappearance of the mycobacteria from the sputum and a change in the radiographic appearance of the lungs. Other criteria which might have been employed, such as a change in weight, sputum volume, temperature, and erythrocyte sedimentation rate, were considered to be insufficiently critical.
The effect of treatment on the course of a disease cannot accurately be assessed without a detailed knowledge of its natural history. Five patients were followed while not being treated. Two who were infected with photochromogens did not start treatment until they had been observed for 21 months (case 8) and three years (case 6) respectively. The former patient became more ill during this period, the sputum persistently contained the organisms, and the extent of radiographic shadowing increased; the latter patient showed no clinical or radiological change, although his sputum was consistently shown to contain the organism. A third patient, who was infected with a group II organism (case 14), was not treated for seven months, during which time there was clinical and radiological worsening and the organisms persisted in the sputum. In two other patients, after ineffective initial chemotherapy, there was an interval of over a year without any treatment. In this time there was radiological evidence of extension of the disease (cases 4 and 10). Thus, of the five patients who were observed while not receiving treatment, in four the disease showed signs of extension and in one it remained apparently static, although the sputum consistently contained the organisms for three years.
Chemotherapy with various combinations of streptomycin, isoniazid, and P.A.S. was given to 20 patients (Table III) . In four, the drugs were stopped in less than two months, a period too short for assessment of any likely therapeutic effect. The remaining 16 patients were given this treatment for periods varying from three months to two and a half years (average duration 13 l months). In only six of these patients did the organisms disappear from the sputum (cases 5, 11, 14, 18, 20, and 25) , and one of them relapsed after chemotherapy had been given for two years. In the other 10 patients, organisms continued to be cultured from the sputum despite treatment, although in two there was some radiological improvement. One patient showed evidence of extension of the disease after two years of treatment (case 22). Thus, measured in this way, the response to the three above-mentioned drugs was poor. There was no correlation between the clinical results and the results of in vitro sensitivity tests, for in each of the six patients who apparently responded to streptomycin, isoniazid, and P.A.S. the strain of mycobacteria was reported as resistant to these drugs. H the patient who died after operation). There is also a correlation with the number of positive sputum cultures. Thus the organisms disappeared from the sputum after treatment in 10 out of 11 patients who produced less than 10 pre-treatment positive cultures and in only six out of 13 patients who produced 10 or more pre-treatment positive cultures.
Of the 25 patients in this series who were followed until 1 November 1966, nine had died. One death followed a thoracotomy and two deaths were from causes unrelated to the main pulmonary disease, namely lobar pneumonia and a road accident. In the remaining six patients the mycobacterial infection was thought to have been only a contributory cause of death; five had either advanced chronic bronchitis or emphysema with terminal respiratory failure and the sixth had widespread pulmonary fibrosis. These patients died between 21 months and seven years after the time of diagnosis.
DISCUSSION
Unclassified mycobacteria are thought to be pathogenic when they are repeatedly isolated from a patient with a chronic inflammatory lesion of the lung for which no other likely cause has been found. The different types of organism all produce clinical, radiological, and pathological features which closely resemble those of classical pulmonary tuberculosis. The most common symptom is a productive cough, often with haemoptysis, but systemic upset such as fever or weight loss is unusual. Cavitation is almost always visible on the radiograph, with surrounding infiltration or fibrosis present in varying degrees. The pathology is indistinguishable from that of tuberculosis, but, although the lymph glands may be involved, haematogenous dissemination rarely, if ever, occurs. If left untreated in some patients the disease apparently remains quiescent while in others it slowly progresses, there being local extension similar to that seen in some cases of indolent tuberculosis.
The principal therapeutic problem arises because most strains of unclassified myobacteria show in vitro resistance to streptomycin, isoniazid, and P.A.S. A favourable response to these drugs, therefore, would not be expected, although the published evidence on this point is conflicting. Thus Christianson and Dewlett (1960) reported that in 22 out of 24 patients infected with photochromogens the organism disappeared from the sputum after this method of treatment (two subsequently relapsed), and Pfuetze, Nuchprayoon, Berg, and Pamintuan (1966) (Kamat, Rossiter, and Gilson, 1961) , in seven out of 15 (Zvetina, 1965) , and in four out of 12 (Kettel, 1965) . Much less information has been published about the response of patients infected with group III organisms. In the only large series to be reported, 22% of 180 patients became 'sputum-negative' after treatment with streptomycin, isoniazid, and P.A.S. (Corpe and Liang, 1960) . In the present series of 16 patients treated in this way, nine of whom had photochromogenic infections, the sputum became negative in six and there was one relapse.
It is difficult to explain why some patients improve when treated with streptomycin, isoniazid, and P.A.S. although the organisms which have been cultured from their sputum show in vitro resistance to these drugs. Either the sensitivity tests are inadequate or the improvement is related to factors other than the chemotherapy. The answer to this question must await the results of a controlled clinical trial; meanwhile the author's policy is to treat these patients with drugs to which their organisms show in vitro sensitivity.
The effectiveness of drugs other than streptomycin, isoniazid, and P.A.S. has yet to be determined and no large trials have been reported. In the present series, out of 10 patients who were given various combinations of these drugs for at least 12 weeks, selected according to in vitro sensitivity tests, there was an apparent response in seven. Treatment for 12 months or longer might have resulted in a higher success rate, but the duration of therapy was frequently limited by drug toxicity. Our general impression is of a limited chance of success whatever the type of chemotherapy used, although it has been reported that the response to treatment is better with organisms from group I than from group III (Jenkins, 1959; Corpe, Runyon, and Lester, 1963; Phillips and Larkin, 1964) . Clinical infection with organisms from group IV presents the biggest problem of treatment, for they are commonly resistant both in vivo and in vitro to all the antituberculosis drugs (see case 15).
Because of the uncertain outcome of medical treatment many patients are treated surgically, most often with success. Thus Jenkins, Bahar, and Chofnas (1960) Corpe (1964) operated on 330 patients with group III infections and concluded that surgical treatment had a 75% chance of success. In our patients a satisfactory surgical result was achieved in eight out of 10 cases. The majority of patients treated surgically are also given chemotherapy, which may contribute to the result.
The reported incidence of post-operative complications is fairly high, particularly bronchopleural fistulae. Harrison, Reimann, Long, Lester, and Adams (1959) performed 14 resections which resulted in three bronchopleural fistulae and two other major complications. Corpe and Liang (1960) reported three fistulae and two haemorrhages after 38 operations, and Law (1964) had eight major complications after 101 operations. In the present series haemorrhage and bronchopleural fistula proved fatal in one patient treated surgically. The relatively high complication rate might arise because of the difficulty in finding an effective combination of drugs for operative cover. However, acute dissemination of the disease is not encountered in the post-operative period.
The overall success rate of combined medical and surgical treatment appears to be greater than that of medical treatment alone. This may partly result from a bias in case selection, for most patients treated surgically have less extensive disease. However, if allowance is made for this factor it still seems that the combined method of treatment is more effective. Therefore it should be considered whenever organisms persist in the sputum after several months of chemotherapy, provided the patient is fit enough and the disease is sufficiently localized. An initial course of chemotherapy is justified, because in a proportion of patients treated in this way the mycobacteria disappeared from the sputum and surgery is unnecessary.
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